122018-92-2

Basic information

• Product Name: CORTICOTROPIN RELEASE-INHIBITING FACTOR
• Synonyms: H-PHE-ILE-ASP-PRO-GLU-LEU-GLN-ARG-SER-TRP-GLU-GLU-LYS-GLU-GLY-GLU-GLY-VAL-LEU-MET-PRO-GLU-OH;FIDPELQRSWEEKEGEGVLMPE;prepro-thyrotropin releasing hormone*fragment 178;PREPRO-THYROTROPIN RELEASING HORMONE*FRA GMENT 178-1;Corticotropin release inhibiting factor, CRIF;CRIF Prepro TRH(178-199);PHE-ILE-ASP-PRO-GLU-LEU-GLN-ARG-SER-TRP-GLU-GLU-LYS-GLU-GLY-GLU-GLY-VAL-LEU-MET-PRO-GLU;PREPRO-THYROTROPIN-RELEASING HORMONE (178-199)
• CAS NO: 122018-92-2
• Molecular Formula: C116H176N28O39S
• Molecular Weight: 2618.87
• Product Categories: Peptide
• Mol File: 122018-92-2.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• Storage Temp.: −20°C
• CAS DataBase Reference: CORTICOTROPIN RELEASE-INHIBITING FACTOR(CAS DataBase Reference)
• NIST Chemistry Reference: CORTICOTROPIN RELEASE-INHIBITING FACTOR(122018-92-2)
• EPA Substance Registry System: CORTICOTROPIN RELEASE-INHIBITING FACTOR(122018-92-2)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 122018-92-2(Hazardous Substances Data)

Usage

Description

Corticotropic release-inhibiting factor, also known as corticotropin release-inhibiting hormone (CRIH), is a neuropeptide hormone primarily produced in the hypothalamus of the brain. It plays a crucial role in regulating the body's response to stress and maintaining homeostasis by inhibiting the secretion of adrenocorticotropic hormone (ACTH) from the pituitary gland, which in turn suppresses the release of cortisol from the adrenal glands. Dysregulation of CRIH can lead to various stress-related disorders, including anxiety and depression. Additionally, research has implicated its role in regulating food intake and potential therapeutic applications for conditions such as obesity and metabolic syndrome.

Uses

Used in Pharmaceutical Industry:
Corticotropic release-inhibiting factor is used as a therapeutic agent for stress-related disorders such as anxiety and depression. Its ability to regulate the body's response to stress and maintain homeostasis makes it a promising candidate for the development of treatments for these conditions.
Used in Obesity and Metabolic Syndrome Treatment:
Corticotropic release-inhibiting factor is used as a potential treatment for obesity and metabolic syndrome due to its role in regulating food intake. By modulating the hormone's activity, it may help control appetite and promote weight loss, offering a novel approach to managing these conditions.
Used in Research:
Corticotropic release-inhibiting factor is used as a research tool to study the mechanisms underlying stress response, homeostasis, and related disorders. Understanding its role in these processes can provide insights into the development of new therapeutic strategies and interventions for various health conditions.

InChI:InChI=1/C116H176N28O39S/c1-10-61(8)95(142-96(163)65(118)51-62-21-12-11-13-22-62)112(179)139-80(53-93(161)162)114(181)144-47-20-27-82(144)109(176)133-74(34-41-91(157)158)104(171)136-77(49-58(2)3)105(172)131-71(29-36-84(119)146)101(168)128-68(26-18-45-122-116(120)121)100(167)140-81(57-145)108(175)137-79(52-63-54-123-66-24-15-14-23-64(63)66)107(174)132-73(33-40-90(155)156)103(170)130-72(32-39-89(153)154)102(169)127-67(25-16-17-44-117)99(166)129-70(31-38-88(151)152)98(165)124-55-85(147)126-69(30-37-87(149)150)97(164)125-56-86(148)141-94(60(6)7)111(178)138-78(50-59(4)5)106(173)134-75(43-48-184-9)113(180)143-46-19-28-83(143)110(177)135-76(115(182)183)35-42-92(159)160/h11-15,21-24,54,58-61,65,67-83,94-95,123,145H,10,16-20,25-53,55-57,117-118H2,1-9H3,(H2,119,146)(H,124,165)(H,125,164)(H,126,147)(H,127,169)(H,128,168)(H,129,166)(H,130,170)(H,131,172)(H,132,174)(H,133,176)(H,134,173)(H,135,177)(H,136,171)(H,137,175)(H,138,178)(H,139,179)(H,140,167)(H,141,148)(H,142,163)(H,149,150)(H,151,152)(H,153,154)(H,155,156)(H,157